Literature DB >> 35261809

A novel HDAC11 inhibitor potentiates the tumoricidal effects of cordycepin against malignant peripheral nerve sheath tumor through the Hippo signaling pathway.

Po-Yuan Huang1, I-An Shih1, Ying-Chih Liao1, Huey-Ling You1, Ming-Jen Lee1.   

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disorder. Clinically, the hallmarks of NF1 include skin pigmentation and cutaneous neurofibroma. Some NF1 patients develop plexiform neurofibroma (PN) since early childhood. Pathologically, PN contains abundant Schwann cells, blood vessels and connective tissues, which may transform into a malignant peripheral nerve sheath tumor (MPNST). MPNST is a highly invasive sarcoma without any effective therapy. Recently, both in vitro and in vivo studies showed that cordycepin can inhibit the growth of MPNST cells. Cordycepin causes cell cycle arrest at G2/M phase and downregulates the protein levels of α-tubulin, p53 and Sp1. Herein, the present study revealed that the HDAC11 inhibitor, FT895, can synergistically enhance the tumoricidal effect of cordycepin against MPNST cells in vitro. Treatment with the combination of cordycepin and FT895 reduced the size of MPNST in the xenograft mouse model. The combined treatment decreased the protein levels of α-tubulin and KIF18A, which may disrupt the microtubule organization leading to the mis-segregation of chromosomes and aneuploidy. Moreover, the expression levels of TEAD1 and its co-activator TAZ, the candidate proteins in hippo signaling pathway, were suppressed after combined treatment. Sequence analysis found a few binding sites for the transcription factor, TEAD1 in the promoter regions of TUBA1B, KIF18A, TEAD1, TAZ, YAP, TP53 and SP1 genes. ChIP-qPCR assay showed that the combined treatment decreases the binding of TEAD1 to the promoters of TUBA1B, KIF18A, TEAD1, TAZ and YAP genes in STS26T cells. The reduced binding to TP53 and SP1 promoters was also found in S462TY cells, which was further confirmed by immunoblotting. The down-regulation of these important transcriptional factors may contribute to the vulnerability of MPNST. In summary, HDAC11 inhibitor, FT895 can potentiate the tumoricidal effect of cordycepin to suppress the MPNST cell growth, which was probably mediated by the dysfunction of hippo-signaling pathway. AJCR
Copyright © 2022.

Entities:  

Keywords:  ChIP-qPCR; FT895; HDAC11 inhibitor; Hippo pathway; MPNST; cordycepin

Year:  2022        PMID: 35261809      PMCID: PMC8899988     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  44 in total

1.  Insights into transcription enhancer factor 1 (TEF-1) activity from the solution structure of the TEA domain.

Authors:  Asokan Anbanandam; Diana C Albarado; Catherine T Nguyen; Georg Halder; Xiaolian Gao; Sudha Veeraraghavan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-03       Impact factor: 11.205

2.  Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

Authors:  Zhenhuan Zhang; Hiroko Yamashita; Tatsuya Toyama; Hiroshi Sugiura; Yoshiaki Ando; Keiko Mita; Maho Hamaguchi; Yasuo Hara; Shunzo Kobayashi; Hirotaka Iwase
Journal:  Breast Cancer Res Treat       Date:  2005-11       Impact factor: 4.872

3.  HDAC11 promotes meiotic apparatus assembly during mouse oocyte maturation via decreasing H4K16 and α-tubulin acetylation.

Authors:  Liyan Sui; Sheng Zhang; Rong Huang; Ziyi Li
Journal:  Cell Cycle       Date:  2020-01-07       Impact factor: 4.534

4.  HDAC6 expression is correlated with better survival in breast cancer.

Authors:  Zhenhuan Zhang; Hiroko Yamashita; Tatsuya Toyama; Hiroshi Sugiura; Yoko Omoto; Yoshiaki Ando; Keiko Mita; Maho Hamaguchi; Shin-Ichi Hayashi; Hirotaka Iwase
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

5.  Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.

Authors:  Eckhard Klieser; Romana Urbas; Stefan Stättner; Florian Primavesi; Tarkan Jäger; Adam Dinnewitzer; Christian Mayr; Tobias Kiesslich; Klaus Holzmann; Pietro Di Fazio; Daniel Neureiter; Stefan Swierczynski
Journal:  Hum Pathol       Date:  2017-02-22       Impact factor: 3.466

Review 6.  Neurofibromatosis type 1: a multidisciplinary approach to care.

Authors:  Angela C Hirbe; David H Gutmann
Journal:  Lancet Neurol       Date:  2014-08       Impact factor: 44.182

7.  Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.

Authors:  Gunnar Johansson; Yonatan Y Mahller; Margaret H Collins; Mi-Ok Kim; Takahiro Nobukuni; John Perentesis; Timothy P Cripe; Heidi A Lane; Sara C Kozma; George Thomas; Nancy Ratner
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

8.  Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53.

Authors:  Nan Bai; Chunyan Zhang; Ning Liang; Zhuhong Zhang; Antao Chang; Jing Yin; Zongjin Li; Na Luo; Xiaoyue Tan; Na Luo; Yunping Luo; Rong Xiang; Xiru Li; Ralph A Reisfeld; Dwayne Stupack; Dan Lv; Chenghu Liu
Journal:  Cancer Biol Ther       Date:  2013-06       Impact factor: 4.742

9.  HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.

Authors:  Lanzhu Yue; Vasundhara Sharma; Nathan P Horvat; Afua A Akuffo; Matthew S Beatty; Cem Murdun; Christelle Colin; Julia M R Billington; William E Goodheart; Eva Sahakian; Ling Zhang; John J Powers; Narmin E Amin; Que T Lambert-Showers; Lancia N Darville; Javier Pinilla-Ibarz; Gary W Reuther; Kenneth L Wright; Chiara Conti; Jennifer Y Lee; Xiaozhang Zheng; Pui Yee Ng; Matthew W Martin; C Gary Marshall; John M Koomen; Ross L Levine; Amit Verma; H Leighton Grimes; Eduardo M Sotomayor; Zonghong Shao; Pearlie K Epling-Burnette
Journal:  Blood       Date:  2020-01-16       Impact factor: 22.113

Review 10.  A short guide to histone deacetylases including recent progress on class II enzymes.

Authors:  Suk-Youl Park; Jeong-Sun Kim
Journal:  Exp Mol Med       Date:  2020-02-19       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.